Skip to main content
Top
Published in: International Journal of Hematology 3/2016

01-03-2016 | Original Article

Genetic variations in complement factors in patients with congenital thrombotic thrombocytopenic purpura with renal insufficiency

Authors: Xinping Fan, Johanna A. Kremer Hovinga, Hiroko Shirotani-Ikejima, Yuka Eura, Hidenori Hirai, Shigenori Honda, Koichi Kokame, Magnus Mansouri Taleghani, Anne-Sophie von Krogh, Yoko Yoshida, Yoshihiro Fujimura, Bernhard Lämmle, Toshiyuki Miyata

Published in: International Journal of Hematology | Issue 3/2016

Login to get access

Abstract

The congenital form of thrombotic thrombocytopenic purpura (TTP) is caused by genetic mutations in ADAMTS13. Some, but not all, congenital TTP patients manifest renal insufficiency in addition to microangiopathic hemolysis and thrombocytopenia. We included 32 congenital TTP patients in the present study, which was designed to assess whether congenital TTP patients with renal insufficiency have predisposing mutations in complement regulatory genes, as found in many patients with atypical hemolytic uremic syndrome (aHUS). In 13 patients with severe renal insufficiency, six candidate complement or complement regulatory genes were sequenced and 11 missense mutations were identified. One of these missense mutations, C3:p.K155Q mutation, is a rare mutation located in the macroglobulin-like 2 domain of C3, where other mutations predisposing for aHUS cluster. Several of the common missense mutations identified in our study have been reported to increase disease-risk for aHUS, but were not more common in patients with as compared to those without renal insufficiency. Taken together, our results show that the majority of the congenital TTP patients with renal insufficiency studied do not carry rare genetic mutations in complement or complement regulatory genes.
Literature
1.
go back to reference Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, McGee BM, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature. 2001;413:488–94.CrossRefPubMed Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, McGee BM, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature. 2001;413:488–94.CrossRefPubMed
2.
go back to reference Kokame K, Matsumoto M, Soejima K, Yagi H, Ishizashi H, Funato M, et al. Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity. Proc Natl Acad Sci. 2002;99:11902–7.PubMedCentralCrossRefPubMed Kokame K, Matsumoto M, Soejima K, Yagi H, Ishizashi H, Funato M, et al. Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity. Proc Natl Acad Sci. 2002;99:11902–7.PubMedCentralCrossRefPubMed
3.
go back to reference Furlan M, Lämmle B. Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease. Best Pract Res Clin Haematol. 2001;14:437–54.CrossRefPubMed Furlan M, Lämmle B. Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease. Best Pract Res Clin Haematol. 2001;14:437–54.CrossRefPubMed
4.
go back to reference Fujimura Y, Matsumoto M, Isonishi A, Yagi H, Kokame K, Soejima K, et al. Natural history of Upshaw–Schulman syndrome based on ADAMTS13 gene analysis in Japan. J Thromb Haemost. 2011;9(Suppl 1):283–301.CrossRefPubMed Fujimura Y, Matsumoto M, Isonishi A, Yagi H, Kokame K, Soejima K, et al. Natural history of Upshaw–Schulman syndrome based on ADAMTS13 gene analysis in Japan. J Thromb Haemost. 2011;9(Suppl 1):283–301.CrossRefPubMed
6.
7.
go back to reference Lemaire M, Fremeaux-Bacchi V, Schaefer F, Choi M, Tang WH, Le Quintrec M, et al. Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat Genet. 2013;45:531–6.PubMedCentralCrossRefPubMed Lemaire M, Fremeaux-Bacchi V, Schaefer F, Choi M, Tang WH, Le Quintrec M, et al. Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat Genet. 2013;45:531–6.PubMedCentralCrossRefPubMed
8.
go back to reference Miyata T, Uchida Y, Ohta T, Urayama K, Yoshida Y, Fujimura Y. Atypical haemolytic uraemic syndrome in a Japanese patient with DGKE genetic mutations. Thromb Haemost; 2015:114:862–3.CrossRefPubMed Miyata T, Uchida Y, Ohta T, Urayama K, Yoshida Y, Fujimura Y. Atypical haemolytic uraemic syndrome in a Japanese patient with DGKE genetic mutations. Thromb Haemost; 2015:114:862–3.CrossRefPubMed
9.
go back to reference Noris M, Bucchioni S, Galbusera M, Donadelli R, Bresin E, Castelletti F, et al. Complement factor H mutation in familial thrombotic thrombocytopenic purpura with ADAMTS13 deficiency and renal involvement. J Am Soc Nephrol. 2005;16:1177–83.CrossRefPubMed Noris M, Bucchioni S, Galbusera M, Donadelli R, Bresin E, Castelletti F, et al. Complement factor H mutation in familial thrombotic thrombocytopenic purpura with ADAMTS13 deficiency and renal involvement. J Am Soc Nephrol. 2005;16:1177–83.CrossRefPubMed
10.
go back to reference Kremer Hovinga JA, Lämmle B. Role of ADAMTS13 in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura. Hematol Am Soc Hematol Educ Program. 2012;2012:610–6. Kremer Hovinga JA, Lämmle B. Role of ADAMTS13 in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura. Hematol Am Soc Hematol Educ Program. 2012;2012:610–6.
11.
go back to reference Mansouri Taleghani M, von Krogh AS, Fujimura Y, George JN, Hrachovinova I, Knobl PN, et al. Hereditary thrombotic thrombocytopenic purpura and the hereditary TTP registry. Hamostaseologie. 2013;33:138–43.CrossRefPubMed Mansouri Taleghani M, von Krogh AS, Fujimura Y, George JN, Hrachovinova I, Knobl PN, et al. Hereditary thrombotic thrombocytopenic purpura and the hereditary TTP registry. Hamostaseologie. 2013;33:138–43.CrossRefPubMed
12.
go back to reference Kremer Hovinga JA, Vesely SK, Terrell DR, Lammle B, George JN. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood. 2010;115:1500–11.CrossRefPubMed Kremer Hovinga JA, Vesely SK, Terrell DR, Lammle B, George JN. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood. 2010;115:1500–11.CrossRefPubMed
13.
go back to reference Froehlich-Zahnd R, George JN, Vesely SK, Terrell DR, Aboulfatova K, Dong JF, et al. Evidence for a role of anti-ADAMTS13 autoantibodies despite normal ADAMTS13 activity in recurrent thrombotic thrombocytopenic purpura. Haematologica. 2012;97:297–303.PubMedCentralCrossRefPubMed Froehlich-Zahnd R, George JN, Vesely SK, Terrell DR, Aboulfatova K, Dong JF, et al. Evidence for a role of anti-ADAMTS13 autoantibodies despite normal ADAMTS13 activity in recurrent thrombotic thrombocytopenic purpura. Haematologica. 2012;97:297–303.PubMedCentralCrossRefPubMed
14.
go back to reference Kato S, Matsumoto M, Matsuyama T, Isonishi A, Hiura H, Fujimura Y. Novel monoclonal antibody-based enzyme immunoassay for determining plasma levels of ADAMTS13 activity. Transfusion. 2006;46:1444–52.CrossRefPubMed Kato S, Matsumoto M, Matsuyama T, Isonishi A, Hiura H, Fujimura Y. Novel monoclonal antibody-based enzyme immunoassay for determining plasma levels of ADAMTS13 activity. Transfusion. 2006;46:1444–52.CrossRefPubMed
15.
go back to reference Fan X, Yoshida Y, Honda S, Matsumoto M, Sawada Y, Hattori M, et al. Analysis of genetic and predisposing factors in Japanese patients with atypical hemolytic uremic syndrome. Mol Immunol. 2013;54:238–46.CrossRefPubMed Fan X, Yoshida Y, Honda S, Matsumoto M, Sawada Y, Hattori M, et al. Analysis of genetic and predisposing factors in Japanese patients with atypical hemolytic uremic syndrome. Mol Immunol. 2013;54:238–46.CrossRefPubMed
16.
go back to reference Matsumoto T, Fan X, Ishikawa E, Ito M, Amano K, Toyoda H, et al. Analysis of patients with atypical hemolytic uremic syndrome treated at the Mie University Hospital: concentration of C3 p. I1157T mutation. Int J Hematol. 2014;100:437–42.CrossRefPubMed Matsumoto T, Fan X, Ishikawa E, Ito M, Amano K, Toyoda H, et al. Analysis of patients with atypical hemolytic uremic syndrome treated at the Mie University Hospital: concentration of C3 p. I1157T mutation. Int J Hematol. 2014;100:437–42.CrossRefPubMed
17.
go back to reference Wu J, Wu YQ, Ricklin D, Janssen BJ, Lambris JD, Gros P. Structure of complement fragment C3b-factor H and implications for host protection by complement regulators. Nat Immunol. 2009;10:728–33.PubMedCentralCrossRefPubMed Wu J, Wu YQ, Ricklin D, Janssen BJ, Lambris JD, Gros P. Structure of complement fragment C3b-factor H and implications for host protection by complement regulators. Nat Immunol. 2009;10:728–33.PubMedCentralCrossRefPubMed
18.
go back to reference Eura Y, Kokame K, Takafuta T, Tanaka R, Kobayashi H, Ishida F, et al. Candidate gene analysis using genomic quantitative PCR: identification of ADAMTS13 large deletions in two patients with Upshaw–Schulman syndrome. Mol Genet Genomic Med. 2014;2:240–4.PubMedCentralCrossRefPubMed Eura Y, Kokame K, Takafuta T, Tanaka R, Kobayashi H, Ishida F, et al. Candidate gene analysis using genomic quantitative PCR: identification of ADAMTS13 large deletions in two patients with Upshaw–Schulman syndrome. Mol Genet Genomic Med. 2014;2:240–4.PubMedCentralCrossRefPubMed
19.
go back to reference Yuasa I, Nakagawa M, Umetsu K, Harihara S, Matsusue A, Nishimukai H, et al. Molecular basis of complement factor I (CFI) polymorphism: one of two polymorphic suballeles responsible for CFI A is Japanese-specific. J Hum Genet. 2008;53:1016–21.CrossRefPubMed Yuasa I, Nakagawa M, Umetsu K, Harihara S, Matsusue A, Nishimukai H, et al. Molecular basis of complement factor I (CFI) polymorphism: one of two polymorphic suballeles responsible for CFI A is Japanese-specific. J Hum Genet. 2008;53:1016–21.CrossRefPubMed
20.
go back to reference Schneppenheim R, Kremer Hovinga JA, Becker T, Budde U, Karpman D, Brockhaus W, et al. A common origin of the 4143insA ADAMTS13 mutation. Thromb Haemost. 2006;96:3–6.PubMed Schneppenheim R, Kremer Hovinga JA, Becker T, Budde U, Karpman D, Brockhaus W, et al. A common origin of the 4143insA ADAMTS13 mutation. Thromb Haemost. 2006;96:3–6.PubMed
21.
go back to reference Heurich M, Martinez-Barricarte R, Francis NJ, Roberts DL, Rodriguez de Cordoba S, Morgan BP, et al. Common polymorphisms in C3, factor B, and factor H collaborate to determine systemic complement activity and disease risk. Proc Natl Acad Sci. 2011;108:8761–6.PubMedCentralCrossRefPubMed Heurich M, Martinez-Barricarte R, Francis NJ, Roberts DL, Rodriguez de Cordoba S, Morgan BP, et al. Common polymorphisms in C3, factor B, and factor H collaborate to determine systemic complement activity and disease risk. Proc Natl Acad Sci. 2011;108:8761–6.PubMedCentralCrossRefPubMed
22.
go back to reference Gold B, Merriam JE, Zernant J, Hancox LS, Taiber AJ, Gehrs K, et al. Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration. Nat Genet. 2006;38:458–62.PubMedCentralCrossRefPubMed Gold B, Merriam JE, Zernant J, Hancox LS, Taiber AJ, Gehrs K, et al. Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration. Nat Genet. 2006;38:458–62.PubMedCentralCrossRefPubMed
23.
go back to reference Roversi P, Johnson S, Caesar JJ, McLean F, Leath KJ, Tsiftsoglou SA, et al. Structural basis for complement factor I control and its disease-associated sequence polymorphisms. Proc Natl Acad Sci. 2011;108:12839–44.PubMedCentralCrossRefPubMed Roversi P, Johnson S, Caesar JJ, McLean F, Leath KJ, Tsiftsoglou SA, et al. Structural basis for complement factor I control and its disease-associated sequence polymorphisms. Proc Natl Acad Sci. 2011;108:12839–44.PubMedCentralCrossRefPubMed
24.
go back to reference Abrera-Abeleda MA, Nishimura C, Frees K, Jones M, Maga T, Katz LM, et al. Allelic variants of complement genes associated with dense deposit disease. J Am Soc Nephrol. 2011;22:1551–9.PubMedCentralCrossRefPubMed Abrera-Abeleda MA, Nishimura C, Frees K, Jones M, Maga T, Katz LM, et al. Allelic variants of complement genes associated with dense deposit disease. J Am Soc Nephrol. 2011;22:1551–9.PubMedCentralCrossRefPubMed
25.
go back to reference Maller JB, Fagerness JA, Reynolds RC, Neale BM, Daly MJ, Seddon JM. Variation in complement factor 3 is associated with risk of age-related macular degeneration. Nat Genet. 2007;39:1200–1.CrossRefPubMed Maller JB, Fagerness JA, Reynolds RC, Neale BM, Daly MJ, Seddon JM. Variation in complement factor 3 is associated with risk of age-related macular degeneration. Nat Genet. 2007;39:1200–1.CrossRefPubMed
26.
go back to reference Yates JR, Sepp T, Matharu BK, Khan JC, Thurlby DA, Shahid H, et al. Complement C3 variant and the risk of age-related macular degeneration. N Engl J Med. 2007;357:553–61.CrossRefPubMed Yates JR, Sepp T, Matharu BK, Khan JC, Thurlby DA, Shahid H, et al. Complement C3 variant and the risk of age-related macular degeneration. N Engl J Med. 2007;357:553–61.CrossRefPubMed
27.
go back to reference Tortajada A, Montes T, Martinez-Barricarte R, Morgan BP, Harris CL, de Cordoba SR. The disease-protective complement factor H allotypic variant Ile62 shows increased binding affinity for C3b and enhanced cofactor activity. Hum Mol Genet. 2009;18:3452–61.PubMedCentralCrossRefPubMed Tortajada A, Montes T, Martinez-Barricarte R, Morgan BP, Harris CL, de Cordoba SR. The disease-protective complement factor H allotypic variant Ile62 shows increased binding affinity for C3b and enhanced cofactor activity. Hum Mol Genet. 2009;18:3452–61.PubMedCentralCrossRefPubMed
28.
go back to reference Montes T, Tortajada A, Morgan BP, de Cordoba SR, Harris CL. Functional basis of protection against age-related macular degeneration conferred by a common polymorphism in complement factor B. Proc Natl Acad Sci. 2009;106:4366–71.PubMedCentralCrossRefPubMed Montes T, Tortajada A, Morgan BP, de Cordoba SR, Harris CL. Functional basis of protection against age-related macular degeneration conferred by a common polymorphism in complement factor B. Proc Natl Acad Sci. 2009;106:4366–71.PubMedCentralCrossRefPubMed
29.
go back to reference Marinozzi MC, Vergoz L, Rybkine T, Ngo S, Bettoni S, Pashov A, et al. Complement factor B mutations in atypical hemolytic uremic syndrome-disease-relevant or benign? J Am Soc Nephrol. 2014;25:2053–65.PubMedCentralCrossRefPubMed Marinozzi MC, Vergoz L, Rybkine T, Ngo S, Bettoni S, Pashov A, et al. Complement factor B mutations in atypical hemolytic uremic syndrome-disease-relevant or benign? J Am Soc Nephrol. 2014;25:2053–65.PubMedCentralCrossRefPubMed
30.
go back to reference Caprioli J, Castelletti F, Bucchioni S, Bettinaglio P, Bresin E, Pianetti G, et al. Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. Hum Mol Genet. 2003;12:3385–95.CrossRefPubMed Caprioli J, Castelletti F, Bucchioni S, Bettinaglio P, Bresin E, Pianetti G, et al. Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. Hum Mol Genet. 2003;12:3385–95.CrossRefPubMed
31.
go back to reference Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol. 2010;5:1844–59.PubMedCentralCrossRefPubMed Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol. 2010;5:1844–59.PubMedCentralCrossRefPubMed
32.
go back to reference Jozsi M, Licht C, Strobel S, Zipfel SL, Richter H, Heinen S, et al. Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency. Blood. 2008;111:1512–4.CrossRefPubMed Jozsi M, Licht C, Strobel S, Zipfel SL, Richter H, Heinen S, et al. Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency. Blood. 2008;111:1512–4.CrossRefPubMed
33.
go back to reference Noris M, Mescia F, Remuzzi G. STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol. 2012;8:622–33.CrossRefPubMed Noris M, Mescia F, Remuzzi G. STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol. 2012;8:622–33.CrossRefPubMed
34.
go back to reference Tati R, Kristoffersson AC, Stahl AL, Rebetz J, Wang L, Licht C, et al. Complement activation associated with ADAMTS13 deficiency in human and murine thrombotic microangiopathy. J Immunol. 2013;191:2184–93.PubMedCentralCrossRefPubMed Tati R, Kristoffersson AC, Stahl AL, Rebetz J, Wang L, Licht C, et al. Complement activation associated with ADAMTS13 deficiency in human and murine thrombotic microangiopathy. J Immunol. 2013;191:2184–93.PubMedCentralCrossRefPubMed
35.
go back to reference Reti M, Farkas P, Csuka D, Razso K, Schlammadinger A, Udvardy ML, et al. Complement activation in thrombotic thrombocytopenic purpura. J Thromb Haemost. 2012;10:791–8.CrossRefPubMed Reti M, Farkas P, Csuka D, Razso K, Schlammadinger A, Udvardy ML, et al. Complement activation in thrombotic thrombocytopenic purpura. J Thromb Haemost. 2012;10:791–8.CrossRefPubMed
Metadata
Title
Genetic variations in complement factors in patients with congenital thrombotic thrombocytopenic purpura with renal insufficiency
Authors
Xinping Fan
Johanna A. Kremer Hovinga
Hiroko Shirotani-Ikejima
Yuka Eura
Hidenori Hirai
Shigenori Honda
Koichi Kokame
Magnus Mansouri Taleghani
Anne-Sophie von Krogh
Yoko Yoshida
Yoshihiro Fujimura
Bernhard Lämmle
Toshiyuki Miyata
Publication date
01-03-2016
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 3/2016
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-015-1933-7

Other articles of this Issue 3/2016

International Journal of Hematology 3/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine